SEATTLE, May 13, 2021, (MEDGADGET) — Laboratory analyzers are self-contained devices that calculate electrolytes in serum. Person biosensor technology is used in benchtop analyzers. Benchtop analyzers have a lower operating cost than portable analyzers.
Drivers:
Rising cases of chronic disorders is expected to boost the growth of EME blood gas and electrolyte analyzers market over the forecast period. Saudi Arabia had 24,485 new cancer cases and 10,518 cancer-related deaths in 2018, according to the World Health Organization.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3971
Furthermore, rising geriatric population is also expected to fuel the growth of EME blood gas and electrolyte analyzers market. The geriatric population in Europe is expected to grow from 894 million in 2019 to 910 million in 2020, according to the World Health Organization. By 2020, the number of people aged 85 and up is predicted to increase from 14 million to 19 million, and by 2050, to 40 million.
In terms of volume, laboratory analyzers dominated the EME blood gas and electrolyte analyzers market in 2019, accounting for 38.1 percent of the market, followed by benchtop analyzers and portable analyzers.
Restraints:
The market’s growth is hindered by a shortage of qualified staff in remote areas to operate blood gas and electrolyte analyzers.
Furthermore, the market growth is expected to be limited by the complex functioning and understanding of data for these analyzers.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3971
Opportunities:
Outbreak of Covid-19 is expected to provide lucrative growth opportunities for players in the EME blood gas and electrolyte analyzers industry. According to the World Health Organization, there were 306,214 confirmed cases of COVID-19 in the United Kingdom from January 31 to 4:44pm CEST on June 24, 2020, with 42,927 deaths.
Furthermore, market growth is expected to be supported by system upgrades. For instance, at the Institute of Biomedical Science (IBMS) Congress 2019, held in the United Kingdom in September 2019, Radiometer Ltd. demonstrated its range of point-of-care solutions, including the ABL90 FLEX PLUS blood gas analyzer with creatinine and urea and the AQT90 FLEX immunoassay analyzer with sepsis biomarkers.
EME blood gas and electrolyte analyzers market was valued at US$ 133.2 Mn in 2019 and is forecast to reach a value of US$ 195.7 Mn by 2027 at a CAGR of 5.0% between 2020 and 2027.
EME blood gas and electrolyte analyzers market is estimated to account for US$ 139.4 Mn in terms of value in 2020 and is expected to reach US$ 195.7 Mn in terms of value by the end of 2027.
Market Taxonomy:
EME Blood Gas and Electrolyte Analyzers Market, By Product, is Segmented into:
- By Product:
- Blood Gas Analyzers
- Electrolyte Analyzers
- Combination Analyzers
- Consumables
- By Modality:
- Laboratory Analyzers
- Benchtop Analyzers
- Portable Analyzers
- By End User:
- Hospitals
- Diagnostic Centres
- Ambulatory Surgical Centres
- Clinics
Market Trends/Key Takeaways:
Key market players are focusing on the approval and launch of new products in order to broaden their product range. For instance, Nova Biomedical received FDA clearance for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use in April 2020.
Blood gas and electrolyte analyzers are vulnerable to cyber-attacks, which can compromise the devices’ confidentiality, credibility, and availability. Siemens Healthineers, for instacne, issued a security alert in June 2018 regarding two cybersecurity flaws in its RAPID blood-gas analyzers.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/eme-blood-gas-and-electrolyte-analyzers-market-3239
Regulations:
EU 5
- The upcoming In-Vitro Diagnostic (IVD) Device Regulation is suggestively different to the current IVD Directive, comprising changed classification rules and necessities for conformity assessment. The proposed Regulation introduces a new risk-rule classification system based on the Global Harmonization Task Force (GHTF) classification rules.
- This alteration to the classification system will have an effect on all manufacturers of IVDs. The majority of IVDs are currently self-certified, but once the Regulation comes into effect, most will need the services of acquainted body to classify their devices.
- In the new classification system, IVD devices will be divided into four Classes of risk: A (lowest risk), B, C and D (highest risk). By using the seven classification rules, devices will be divided into one of the four classes that will dictate notified body involvement
- The new Regulation will become applicable five years after its entry into force, to take into account the significant changes to the classification system for IVDs and to the conformity assessment procedures.
Competitive Landscape:
Major players operating in EME blood gas and electrolyte analyzers market include Siemens Healthcare, Alere Inc., EKF Diagnostics, ERBA Diagnostics Mannheim GmbH, Abbott Laboratories, Medica Corporation, Nova Biomedical, Radiometer Medical ApS, F. Hoffmann-La Roche Ltd., and Instrumentation Laboratories (Werfen).
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/3971
Key Developments:
In April 2020, Nova Biomedical launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries.
In April 2020, In North America, Europe, and the Middle East, Accelerate Diagnostics, Inc. partnered with BioCheck, Inc. to distribute the BioCheck MS-FAST, a completely automated chemiluminescence immunoassay analyzer, as well as BioCheck’s SARS-CoV-2 tests for the detection of IgG and IgM antibodies.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837